Located in Milwaukee, Wisconsin, the Versiti Blood Research Institute (VBRI) is the largest blood-focused research institute in the United States. With over 30 basic, translational, and clinical investigators, the institute is dedicated to advancing scientific knowledge and developing innovative therapies related to blood and blood disorders. The institute's research interests encompass a wide range of topics, including transfusion medicine, cellular therapy, thrombosis/hemostasis, immunology, and hematologic malignancies. As a vital part of Versiti, a non-profit organization with a blood bank at its core, the VBRI strives to improve lives through innovative research and the development of novel diagnostics and treatments.
VBRI is part of the Milwaukee Regional Medical Campus, a rapidly growing clinical-translational research hub. VBRI’s proximity to the Medical College of Wisconsin, Childrens’ Hospital of Wisconsin, and Froedtert Hospital facilitates seamless interdisciplinary collaborations. A range of exemplary core facilities support highly competitive research. In the summer of 2024, construction of a new research building began, doubling existing VBRI research space to enable the recruitment of 10-15 new faculty. With its renowned researchers, strategic expansion plans and location in a highly collaborative environment, the VBRI is poised to maintain and expand its position as one of the leading hematology institutes in the world
Develops, improves, and implements laboratory techniques and performs complex experiments or tests to contribute to the timely and accurate completion of the research project(s).
The Pradhan-Sundd Lab has research interests in the following areas:
The role of hemolysis in sickle cell disease organ injury:
Hemolysis is a key characteristic of sickle cell disease (SCD) that contributes to the disease pathogenesis and clinical heterogeneity. In SCD, cell free hemoglobin and its byproducts (heme and iron) cause vasculopathy as well as a slew of clinical consequences, including liver failure. Although liver injury affects up to ~40% of hospitalized SCD patients, therapeutic approaches to prevent liver injury in SCD are limited. In the Pradhan-Sundd lab we are interested in understanding the molecular (signalling) mechanism of hemolysis induced acute and chronic liver injury. We are also investigating the processes of hepatic hemoglobin, heme, and iron clearance in SCD.
Sinusoidal endothelium driven liver directed gene therapy in hemophilia:
Hemophilia A is an X-linked recessive bleeding disorder caused by the absence of coagulation factor- VIII (FVIII). Individuals who are affected are at risk of spontaneous bleeding into joints which can be life threatening. Recent advances in liver-directed gene transfer suggest that gene therapy can successfully treat hemophilia A. FVIII is produced in the liver sinusoidal endothelial cells. Thus, liver sinusoidal endothelial cell viability and functioning are important for successful liver directed gene transfer in Hemophilia. We have recently shown liver sinusoidal endothelial maladaptive structural changes in FVIII-deficient mice and their deleterious impact on the efficacy of liver-directed gene transfer. Abnormal endothelial function was recently recognized in patients with hemophilia A. Our current research focuses on investigating the molecular mechanisms that contribute to the loss of endothelial fenestration in individuals with FVIII deficiency, and how this loss impacts liver-directed gene therapy in patients with hemophilia.
Benefits
Versiti provides a comprehensive benefits package based on your job classification. Full-time regular employes are eligible for Medical, Dental, and Vision Plans, Paid Time Off (PTO) and Holidays, Short- and Long-term disability, life insurance, 7% match dollar for dollar 401(k), voluntary programs, discount programs, others.
Education
Experience
Knowledge, Skills and Abilities
#LI-EH1
#LI-Onsite
#VBRI